Ari-0001
B-Cell Adult Acute Lymphocytic Leukemia
Explore 23 assets in B-Cell Adult Acute Lymphocytic Leukemia →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
GUSTAVO SALGUERO
Modality
Cell therapy
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07412405CT.gov This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Adult Acute Lymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ari-0001 (this asset) | GUSTAVO SALGUERO | N/A | D · 30 |
| Vincristine Sulfate | SWOG Cancer Research Network | P3 | BBB |
| Pegaspargase | National Cancer Institute (NCI) | P3 | BBB |
| Cytarabine | Massachusetts General Hospital | P3 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Soochow University | P3 | BBB |
| Dexasone | Mayo Clinic | P3 | BBB |
| Prednisone | SWOG Cancer Research Network | P3 | BBB |
| Methotrexate | Massachusetts General Hospital | P3 | BBB |
| Daunomycin | Children's Oncology Group | P3 | BBB |
+42 more in the B-Cell Adult Acute Lymphocytic Leukemia cohort
Other indications for Ari-0001
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P2 | B · 62 |
| Non-Hodgkin Lymphoma | — | P2 | CCC · 53 |
| Acute Lymphoblastic Leukemia | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ari-0001 in B-Cell Adult Acute Lymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ari-0001-b-cell-adult-acute-lymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →